ArticleMolecular and cellular pediatrics2025
Acid β-glucosidase (GBA1) gene mutational spectrum and clinical phenotypes in patients with gaucher disease: seven novel mutations in a multicenter retrospective cohort study from upper Egypt.
Article in Molecular and cellular pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to identify GBA1 variants in Egyptian Gaucher disease (GD) patients residing in a region with high consanguinity and to correlate these genotypes with their clinical phenotypes. METHODOLOGY: This descriptive study included 68 Egyptian patients diagnosed with GD. Diagnosis relied upon reduced β-glucocerebrosidase activity measured by tandem mass spectrometry from dried blood spots and confirmed by GBA1 single-gene sequencing. Clinical and laboratory information were gathered from patient records, and neurological evaluations were conducted by a neurologist.
resultsThirty patients (44.1%) were classified as type 1 GD, three (4.4%) as type 2 GD, and 35 patients (51.5%) as type 3 GD. Variant analysis of the 136 alleles identified 19 different variants. The most prevalent mutant allele was c.1448T > C p.(Leu483Pro) (50.7%). Seven novel variants were documented: five homozygous missense variants, including c.263 C > T p.(Met88Thr), c.1331 A > G p.(Asp444Gly), c.1409 C > T p.(Ser470Phe), c.907 C > G p.(Leu303Val), c.1574G > A p.(Gly525Asp), two heterozygous missense variants: c.380 C > G p.(Ala127Gly) and c.453 + 2T > C. All carriers of these novel variants were phenotypically classified as type 1 GD. Genotype-phenotype correlations confirmed that the c.1226 A > G p.(Asn409Ser) variant was confined to type 1 GD, whereas c.1448T > C p.(Leu483Pro) was associated with types 2 and 3 GD.
conclusionVariant analysis of 136 alleles identified 19 GBA1 variants, including seven novel variants. These findings enhance genotype-phenotype correlations, provide genetic counseling, and enable customized molecular analyses for families at risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.